Simple blood test may spot sickest preterm infants

NCT ID NCT07154134

Recruiting now Diagnosis Sponsor: Tanta University Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study looks at two substances in the blood—endocan and copeptin—in 40 premature babies born between 28 and 36 weeks who have breathing trouble (respiratory distress syndrome). Researchers will measure these markers on the first day of life to see if they can predict how severe the breathing problem is and the risk of death. The goal is to find a simple way to identify which babies need the most urgent care.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this could help doctors quickly identify which preterm babies need more intensive breathing support.
What could go wrong: This is a small, early study with only 40 babies. The markers may not reliably predict severity or outcomes in larger, more diverse groups.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COPEPTIN are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

adult acute respiratory distress syndrome diabetes insipidus respiratory distress syndrome in premature infants

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COPEPTIN ENDOCAN PRETERM NEONATES RESPIRATORY DISTRESS SYNDROME SERUM

Contacts and locations

Locations

Tanta University
RECRUITING

Tanta, El-Gharbia, 31527, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.